{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.04","value":"-14.29"},{"groupId":"OG001","spread":"14.48","value":"-20.99"},{"groupId":"OG002","spread":"13.47","value":"-23.18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"224"},{"groupId":"OG002","value":"219"}],"units":"Participants"}],"description":"• The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.","dispersionType":"Standard Deviation","groups":[{"description":"Placebo administered orally once daily through Week 24.\n\n. Participants continued to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study.","id":"OG000","title":"Placebo"},{"description":"Baricitinib 2 mg administered orally once daily through Week 24.\n\nParticipants continued to take background cDMARD therapy throughout study.","id":"OG001","title":"Baricitinib 2 mg"},{"description":"Baricitinib 4 mg administered orally once daily through Week 24.\n\nParticipants continued to take background cDMARD therapy throughout study.","id":"OG002","title":"Baricitinib 4 mg"}],"paramType":"MEAN","populationDescription":"mITT population: all randomized participants who received at least 1 dose of the study drug, with a baseline value and at least 1 post-baseline value. Missing values due to discontinuation of study or drug, rescue, or missing data were imputed using modified last observation carried forward (mLOCF) .","reportingStatus":"POSTED","timeFrame":"Baseline, Week 24","title":"Change From Baseline in Measures of Clinical Disease Activity Index (CDAI) Score","type":"SECONDARY","unitOfMeasure":"units on a scale"}